12:00 AM
Oct 01, 2007
 |  BioCentury  |  Strategy

Partnering with sanofi-aventis

Partnering with sanofi-aventis

sanofi-aventis Group (Euronext:SAN; SNY) plans to increase its development activities in biologics via acquisitions and licensing deals. SAN is aiming to have 20% of its entire pipeline of NMEs made up of biologics by 2010, up from about 10% now....

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >